QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the ...

The latest announcement is out from Qiagen ( (QGEN) ).

Qiagen NV CEO Thierry Bernard said the company is working with Moelis & Co. and Goldman Sachs to review its strategic alternatives. "We are no ...

Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:30 AM EDTCompany ParticipantsRoland Sackers - CFO, MD & Member ...

Qiagen ( (QGEN)) has provided an announcement. QIAGEN N.V. disclosed a managers’ transaction involving supervisory board member Toralf Haag, in line with EU market abuse regulations governing insider ...

Qiagen’s next-generation sequencing tests are already used to look for genetic variants that may shed light on an individual’s specific case of cancer and potential treatment options, but the ...

Qiagen has entered a commercial collaboration and joint marketing agreement with French company ID Solutions to expand the availability of digital polymerase chain reaction (dPCR) assays for ...

A month has gone by since the last earnings report for Qiagen (QGEN). Shares have lost about 9.4% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent ...

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow ...

Earlier this year, up-and-coming biotech Neuron23 nominated its first clinical candidate, a small-molecule drug designed to inhibit the LRRK2 gene, mutations in which are commonly linked to inherited ...

QIAGEN N.V. QGEN recently signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.